<DOC>
	<DOCNO>NCT01545726</DOCNO>
	<brief_summary>This study ass safety efficacy QAW039 add current therapy patient sputum eosinophilia persistent asthma .</brief_summary>
	<brief_title>Safety Efficacy QAW039 Sputum Eosinophilia Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<criteria>1 . Written informed consent must obtain assessment perform . 2 . Physician diagnosis asthma , per GINA guideline GINA guideline currently prescribe ICS ICSLABA therapy . 3 . Patients demonstrate reversible airway obstruction , significant FEV1 variability airway hyperresponsiveness ( AHR ) , show response previous test ( ) within last five year . 4 . An ACQ score ≥ 1.5 randomization ≥ 1 exacerbation ( require high patient 's normal dose OCS IV corticosteroid ≥ 3 day ) past 12 month . The definition exacerbation include episode patient selfadministered high dos OCS part document selfmanagement plan initiate patient 's general practitioner respiratory physician . 5 . Patients currently GINA step 2 step 5 asthma therapy . 6 . Sputum eosinophil count ≥ 2 % screening . 1 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . 2 . History hypersensitivity study drug drug similar chemical class ( CRTH2 antagonists ) . 3 . History long QT syndrome whose QTc interval ( Fridericia 's ) prolong &gt; 450 msec male &gt; 470 msec female screen baseline . 4 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 5 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) . 6 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception study treatment 5 day ( 5 halflives ) treatment . 7 . Acute illness asthma , investigator 's opinion , may compromise wellbeing patient study endpoint assessment start study 8 . Patients consider unsuitable inclusion assess physician due serious comorbidities cancer , emphysema significant bronchiectasis . 9 . Recent ( within 6 week screen ) current low respiratory tract infection . 10 . Patients hospitalize require highdose ( &gt; 10mg prednisolone/day ) oral corticosteroid ( OCS ) therapy within 6 week screen visit . 11 . Patients clinically significant laboratory abnormality ( associate study indication ) screening . 12 . Patients clinically significant abnormality 12lead ECG record within one month prior screen . 13 . Patients body mass index ( BMI ) &lt; 17 &gt; 40 kg/m2 . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Sputum eosinophilia</keyword>
	<keyword>CRTH2 receptor</keyword>
	<keyword>PGD2 antagonist</keyword>
</DOC>